Iowa House Bill HF2310

Iowa 2025-2026 Regular Session

• Introduced: 2/6/26
• Refer: 2/6/26

Caption

A bill for an act providing a standing appropriation to the state board of regents for pediatric cancer research at the university of Iowa hospitals and clinics.(Formerly HF 2057; See HF 2758.)

Impact

The introduction of HF2310 represents a significant investment in pediatric cancer research and reflects the state's commitment to improving health outcomes for children battling cancer. By ensuring a consistent funding stream sourced from the general fund, the bill is designed to facilitate ongoing research activities without the burden of administrative costs, as these funds are strictly prohibited from being allocated to overheads or unrelated activities. The requirement for annual reporting to both the governor and the General Assembly further ensures transparency and accountability concerning the use of the appropriated funds.

Summary

House File 2310 seeks to establish a standing appropriation to support pediatric cancer research at the University of Iowa hospitals and clinics. Specifically, the bill stipulates that for each fiscal year beginning July 1, 2026, an amount equating to one dollar per state resident, as per the latest census estimate, will be allocated to the state Board of Regents. The maximum annual funding allowed under the bill is capped at three million dollars. This initiative aims to bolster research efforts directed towards pediatric cancers, thereby contributing to advancements in laboratory research and clinical trials for young patients.

Contention

While the bill presents a focused approach to enhancing pediatric cancer research, potential points of contention could arise regarding the sustainability of this funding model over the long term, particularly considering varying state budgets. Critics might express concerns about the bill's reliance on census figures that could lead to unpredictable funding levels based on population changes. Additionally, there could be discussions regarding the prioritization of funds for pediatric cancer research compared to other critical health priorities within the state budget.